A5009190675- Renal cell carcinoma treatment
- Prostate Cancer Treatment and Research
- Cancer Genomics and Diagnostics
- Renal and related cancers
- Radiopharmaceutical Chemistry and Applications
- Cancer Immunotherapy and Biomarkers
- Bladder and Urothelial Cancer Treatments
- Medical Imaging Techniques and Applications
- Mass Spectrometry Techniques and Applications
- Genetic factors in colorectal cancer
- Cancer, Hypoxia, and Metabolism
- Epigenetics and DNA Methylation
- Prostate Cancer Diagnosis and Treatment
- Cancer, Lipids, and Metabolism
- Advanced Breast Cancer Therapies
- Economic and Financial Impacts of Cancer
- Hormonal and reproductive studies
- Tissue Engineering and Regenerative Medicine
- Ferroptosis and cancer prognosis
- Brain Metastases and Treatment
- Renal Diseases and Glomerulopathies
- CAR-T cell therapy research
- Cancer Research and Treatments
- Cancer Treatment and Pharmacology
- Urinary and Genital Oncology Studies
Cornell University
2016-2025
Weill Cornell Medicine
2016-2025
NewYork–Presbyterian Hospital
2015-2025
New York Hospital Queens
2015-2025
Presbyterian Hospital
2015-2025
Philippine General Hospital
2024
Lander Institute
2016-2024
Hospital Universitario de La Princesa
2024
El Hospital General de Agudos Carlos G. Durand
2021-2022
College Medical Center
2020
Upper tract urothelial carcinoma (UTUC) is characterized by a distinctly aggressive clinical phenotype. To define the biological features driving this phenotype, we performed an integrated analysis of whole-exome and RNA sequencing UTUC. Here report several key insights from our molecular dissection disease: 1) Most UTUCs are luminal-papillary; 2) UTUC has T-cell depleted immune contexture; 3) High FGFR3 expression enriched in correlates with its microenvironment; 4) Sporadic lower total...
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary point, may be published when key planned co-primary or secondary analyses are not yet available. trial updates provide an opportunity to disseminate additional results from studies, in JCO elsewhere, for which point has already been reported. We present final prespecified overall survival (OS) analysis of open-label, phase III CLEAR study treatment-naïve...
Abstract BACKGROUND: Simultaneous inhibition of the vascular epithelial growth factor (VEGF) and mammalian target rapamycin (mTOR) pathway may improve treatment response in advanced renal cell carcinoma (RCC). Everolimus, an oral mTOR inhibitor, sunitinib, tyrosine kinase inhibitor targeting VEGF, are standard agents management metastatic RCC. METHODS: Sequential cohorts 3 to 6 patients with RCC received dose‐escalated combinations sunitinib (37.5 or 50 mg daily, 4 weeks on/2 off) everolimus...
Background Prostate cancer is radiosensitive. Prostate‐specific membrane antigen (PSMA) selectively overexpressed on advanced, castration‐resistant tumors. Lutetium‐177–labeled anti‐PSMA monoclonal antibody J591 ( 177 Lu‐J591) targets prostate with efficacy and dose‐response/toxicity data when delivered as a single dose. Dose fractionation may allow higher doses to be administered safely. Method Men metastatic refractory or refusing standard treatment options normal neutrophil platelet...
The open-label phase IIIb/IV CheckMate 374 study (NCT02596035) was conducted to validate the safety and efficacy of flat-dose nivolumab 240 mg every 2 weeks (Q2W) in previously treated advanced/metastatic renal cell carcinoma. Three cohorts included patients with predominantly clear histology, non-clear histologies, or brain metastases. We report from advanced RCC (nccRCC) cohort 374.Eligible received 0 3 prior systemic therapies. Patients Q2W for ≤24 months until confirmed progression...
Abstract Lessons Learned Our results highlight additional toxicities of dual PI3K/mTOR inhibition in the clinical setting that were unforeseen from preclinical models. Because toxicity and lack efficacy, BEZ235 should not be further developed current formulation for patients with renal cell carcinoma. Background. Allosteric inhibitors mammalian target rapamycin complex 1 (mTORC1) are approved advanced carcinoma (RCC). Preclinical models have suggested phosphatidylinositol 3-kinase (PI3K)...
Non-clear cell renal carcinoma (nccRCC) accounts for ≤20% of RCC cases. Lenvatinib (a multitargeted tyrosine kinase inhibitor) in combination with everolimus (an mTOR is approved the treatment advanced after one prior antiangiogenic therapy.To determine safety and efficacy lenvatinib plus as a first-line patients nccRCC.This open-label, single-arm, multicenter, phase 2 study enrolled unresectable or metastatic nccRCC no anticancer therapy disease.Lenvatinib (18 mg) (5 orally once daily.The...
PURPOSE Novel therapies are needed to extend survival in metastatic castration-resistant prostate cancer (mCRPC). Prostate-specific membrane antigen (PSMA), a cell surface overexpressed PC, provides validated target. This dose-escalation study investigated the safety, efficacy, maximum tolerated dose (MTD), and recommended phase II (RP2D) for 225 Ac-J591, anti-PSMA monoclonal antibody J591 radiolabeled with alpha emitter actinium-225. METHODS Following investigational new drug-enabling...
LBA4517 Background: A preplanned interim analysis of COU-AA-301 showed that AA, a selective androgen biosynthesis (CYP17) inhibitor, significantly improves OS in mCRPC. This is the first phase III study to prospectively assess CTC as surrogate biomarker part regulatory qualification process, here using updated data. Methods: 1,195 patients (pts) with mCRPC post docetaxel were randomized 2:1 AA (1 g QD) + P (5 mg BID) (n = 797) or placebo 398). CTCs (screening and baseline [BL]; BL at weeks...
Lenvatinib is an oral multi-targeted tyrosine kinase inhibitor of VEGFR1-3, FGFR1-4, PDGFRβ, RET, and KIT. Everolimus mammalian target rapamycin approved for advanced renal cell carcinoma (RCC). This phase 1b study assessed safety, maximum tolerated dose (MTD), preliminary antitumor activity lenvatinib plus everolimus in metastatic RCC (mRCC) patients. Patients with unresectable or mRCC Eastern Cooperative Oncology Group performance status 0–1 were eligible (number prior treatments not...
Purpose The decreased effectiveness of single-agent targeted therapies in advanced non-clear cell renal carcinoma (ncRCC) compared with clear (RCC) supports the study combination regimens. We evaluated efficacy everolimus plus bevacizumab patients metastatic ncRCC. Patients and Methods In this single-center phase II trial, treatment-naive received 10 mg oral once per day mg/kg intravenously every 2 weeks. primary end point was progression-free survival (PFS) at 6 months. Correlative analyses...
Background Systemic therapy (ST) can be deferred in patients who have metastatic renal cell carcinoma (mRCC) and slow‐growing metastases. Currently, this subset of managed with active surveillance (AS) is not well described the literature. Methods This was a prospective observational study mRCC across 46 US community academic centers. The objective to describe baseline characteristics demographics initially by AS, reasons for patient outcomes. Descriptive statistics were used characterize...
Advanced urothelial cancer is a frequently lethal disease characterized by marked genetic heterogeneity